0       0

AST 2013 - Cutting Edge of Transplantation


SA06 - Is There a Role for Bortezomib?


Feb 16, 2013 11:00am ‐ Feb 16, 2013 11:30am

Description

Strategic development of antihumoral therapies provides a means for achieving enhanced therapeutic results. The basic immunobiology of humora alloresponses is currently adequate to allow development of new therapies. Plasma cell targeted therapy is one example of new treatment paradigms based on known immunobiology. This talk will describe the biologic basis for plasma cell targeting in general, and for proteasome inhibition in particular.

What You'll Take Away from His Talk:

  • Substantial evidence exists from basic research that plasma cell targeted therapy may provide a viable means for mitigating humoral alloresponses.
  • Initial evidence from clinical experiences with proteasome inhibition indicate that proteasome inhibitor-based regimens offer therapeutic potential.
  • Substantial opportunities exist for enhancing proteasome inhibitor therapy via combinatorial strategies.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content